<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--  EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!--  Version: 6.9.2 -->
<!--  Round: 3dca6a3a-0622-4189-9808-a0f5e81a24b4 -->
<!--  Creation date: 2011-05-05T20:53:52Z -->
<!--  Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.us/dei/2009-01-31" xmlns:dei-ent="http://xbrl.us/dei-ent/2009-01-31" xmlns:dei-std="http://xbrl.us/dei-std/2009-01-31" xmlns:negated="http://xbrl.us/us-gaap/negated/2008-03-31" xmlns:us-gaap="http://xbrl.us/us-gaap/2009-01-31" xmlns:us-gaap-ent="http://xbrl.us/us-gaap-ent/2009-01-31" xmlns:us-roles="http://xbrl.us/us-roles/2009-01-31" xmlns:us-types="http://xbrl.us/us-types/2009-01-31" xmlns:wcrx="http://www.wcrx.com/20110331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="wcrx-20110331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE670978--1110-Q0003_STD_0_20100331_0" unitRef="iso4217_USD" decimals="-3">246000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">200667000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">59881000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">3942000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">17087000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">5154945000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">877653000</us-gaap:AssetsCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">24589000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="shares" decimals="INF">253789788</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="shares" decimals="INF">253789788</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">2538000</us-gaap:CommonStockValue>
  <us-gaap:Goodwill contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">1028550000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">2869916000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InventoryNet contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">117037000</us-gaap:InventoryNet>
  <us-gaap:Liabilities contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">5217762000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">5154945000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">916480000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">143763000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">4115605000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">159411000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">185677000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PrepaidTaxes contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">20633000</us-gaap:PrepaidTaxes>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">219415000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ReceivablesNetCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">327382000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">-86384000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">-62817000</us-gaap:StockholdersEquity>
  <wcrx:AccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">688247000</wcrx:AccruedExpensesAndOtherCurrentLiabilities>
  <wcrx:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20110331_0" unitRef="iso4217_USD" decimals="-3">211934000</wcrx:PrepaidExpenseAndOtherAssetsCurrent>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE670978--1110-Q0003_STD_0_20110429_0" unitRef="shares" decimals="INF">253872732</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE670978--1110-Q0003_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">539006000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">401807000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">98525000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-15645000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">9805000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:Assets contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">5651989000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1177040000</us-gaap:AssetsCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">24176000</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="shares" decimals="INF">252527004</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="shares" decimals="INF">252527004</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">2525000</us-gaap:CommonStockValue>
  <us-gaap:Goodwill contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1028550000</us-gaap:Goodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">3016741000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InventoryNet contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">119497000</us-gaap:InventoryNet>
  <us-gaap:Liabilities contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">5717631000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">5651989000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1123442000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">269911000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">4408753000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">193949000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">185436000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PrepaidTaxes contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">49385000</us-gaap:PrepaidTaxes>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">235709000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ReceivablesNetCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">368537000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-62327000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-65642000</us-gaap:StockholdersEquity>
  <wcrx:AccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">730830000</wcrx:AccruedExpensesAndOtherCurrentLiabilities>
  <wcrx:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE670978--1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">237814000</wcrx:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:CommitmentsAndContingencies2009 contextRef="eol_PE670978--1110-Q0003_STD_365_20101231_0" xsi:nil="true" />
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-293006000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">27512000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">160912000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">217436000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:Depreciation contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">7491000</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.07</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.07</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-2322000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-40649000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">26003000</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-23406000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">29988000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-517567000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-18362000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">245245000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-17243000</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">2900000</us-gaap:PaymentsToAcquireIntangibleAssets>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">15462000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-70000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">1838000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RepaymentsOfSubordinatedDebt contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">89460000</us-gaap:RepaymentsOfSubordinatedDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">31148000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">761302000</us-gaap:Revenues>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">51846000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueNet contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">709456000</us-gaap:SalesRevenueNet>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">320057000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">4683000</us-gaap:ShareBasedCompensation>
  <wcrx:FairValueWriteUpOfAcquiredInventory contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">105504000</wcrx:FairValueWriteUpOfAcquiredInventory>
  <wcrx:IncreaseDecreaseInIncomeTaxesAndOtherNet contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-110984000</wcrx:IncreaseDecreaseInIncomeTaxesAndOtherNet>
  <wcrx:InterestExpenseNet contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">72398000</wcrx:InterestExpenseNet>
  <wcrx:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">22541000</wcrx:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
  <wcrx:IncreaseDecreaseAccountsReceivablePrepaidAndOtherAssets contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">-74817000</wcrx:IncreaseDecreaseAccountsReceivablePrepaidAndOtherAssets>
  <wcrx:RepaymentsOfPriorBankDebt contextRef="eol_PE670978--1110-Q0003_STD_90_20100331_0" unitRef="iso4217_USD" decimals="-3">429875000</wcrx:RepaymentsOfPriorBankDebt>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:TradingSymbol contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">WCRX</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">Warner Chilcott plc</dei:EntityRegistrantName>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">2011-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">0001323854</dei:EntityCentralIndexKey>
  <dei:EntityFilerCategory contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:AmendmentFlag contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">false</dei:AmendmentFlag>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-201140000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;17. Reliance on
Significant Suppliers&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In the event
that a significant supplier (including a third-party manufacturer
or supplier of certain active pharmaceutical ingredients, or
&amp;#x201C;API&amp;#x201D;) suffers an event that causes it to be unable to
manufacture the Company&amp;#x2019;s product or meet the Company&amp;#x2019;s
API requirements for a sustained period and the Company is unable
to obtain the product or API from an alternative supplier, the
resulting shortages of inventory could have a material adverse
effect on the business of the Company. The following table shows
revenue generated from products by significant supplier as a
percentage of total revenues.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="72%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter
Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter
Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Lonza Inc&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;31%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;34%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Cambrex
Corporation&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;23%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;19%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Bayer&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;20%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;13%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;LEO Pharma&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;10%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:AmortizationOfFinancingCosts contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">85350000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">147645000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;7. Sanofi Collaboration
Agreement&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company and
Sanofi-Aventis U.S. LLC (&amp;#x201C;Sanofi&amp;#x201D;) are parties to an
agreement to co-promote ACTONEL on a global basis, excluding Japan
(as amended, the &amp;#x201C;Collaboration Agreement&amp;#x201D;). ATELVIA,
the Company&amp;#x2019;s next generation risedronate sodium
delayed-release product approved by the U.S. Food and Drug
Administration (&amp;#x201C;FDA&amp;#x201D;) in October 2010, is also
marketed in the United States pursuant to the Collaboration
Agreement. The Company&amp;#x2019;s and Sanofi&amp;#x2019;s rights and
obligations are specified by geographic market. In certain
geographic markets, the Company and Sanofi share selling and
advertising and promotion (&amp;#x201C;A&amp;amp;P&amp;#x201D;) costs as well as
product profits based on contractual percentages. In the geographic
markets where the Company is deemed to be the principal in
transactions with customers, the Company recognizes all revenues
from sales of the product along with the related product costs. In
geographic markets where the Company is not the principal in
transactions with customers, revenue is recognized on a net basis,
in other revenue for amounts earned based on Sanofi&amp;#x2019;s sale
transactions with its customers. The Company&amp;#x2019;s share of
selling, A&amp;amp;P and contractual profit sharing expenses are
recognized in SG&amp;amp;A expenses. For the quarter ended
March&amp;#xA0;31, 2011, the Company recognized net sales and other
revenue related to ACTONEL of $209,490 and $22,161, respectively,
and co-promotion expenses of $58,876 were recognized in SG&amp;amp;A
expense. For the quarter ended March&amp;#xA0;31, 2010, the Company
recognized net sales and other revenue related to ACTONEL of
$235,722 and $26,586, respectively, and co-promotion expenses of
$107,094 were recognized in SG&amp;amp;A expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In April 2010,
the Company and Sanofi entered into an amendment to the
Collaboration Agreement. Under the terms of the amendment, the
Company took full operational control over the promotion, marketing
and research and development (&amp;#x201C;R&amp;amp;D&amp;#x201D;) decisions for
ACTONEL and, since the Company commenced its promotional efforts in
early 2011, ATELVIA in the United States and Puerto Rico, and
assumed responsibility for all associated costs and expenses
relating to those activities. Prior to the amendment, the Company
shared such costs with Sanofi in these territories. The Company
remained the principal in transactions with customers in the United
States and Puerto Rico and continues to invoice all sales in these
jurisdictions. In return, it was agreed that Sanofi would receive,
as part of the global collaboration agreement between the parties,
payments from the Company based on an agreed upon percentage of
U.S. and Puerto Rico net sales for the remainder of the term of the
Collaboration Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;In connection
with the Collaboration Agreement, the Company is also party to two
related supply agreements, including a tablet supply agreement
pursuant to which a portion of the Company&amp;#x2019;s ACTONEL product
requirements are manufactured and supplied by Sanofi. The Company
has exercised its right to terminate the tablet supply agreement
with Sanofi, effective May 2012. The Company and Sanofi have been
involved in discussions as to whether the termination of the tablet
supply agreement results in the termination of the Collaboration
Agreement. The Company believes that its termination of the tablet
supply agreement results in the termination of the Collaboration
Agreement in May 2012. Sanofi disagrees and instead believes that
the Collaboration Agreement will remain in effect until
January&amp;#xA0;1, 2015, the original expiration date of the
agreement. On March&amp;#xA0;2, 2011, the Company&amp;#x2019;s subsidiary,
Warner Chilcott Company, LLC (&amp;#x201C;WCCL&amp;#x201D;), and Sanofi each
filed a separate demand for arbitration with the American
Arbitration Association pursuant to the dispute resolution
provisions of the Collaboration Agreement.&amp;#xA0;The WCCL demand
seeks declaratory relief that the Collaboration Agreement will
terminate in May 2012. The Sanofi demand, by contrast, seeks
declaratory relief that termination of the tablet supply agreement
will not result in the cross-termination of the Collaboration
Agreement and that WCCL&amp;#x2019;s assertion of the cross-termination
violates a covenant of good faith and fair dealing contained in the
Collaboration Agreement, as well as unspecified monetary damages.
While the Company believes the terms of the Collaboration Agreement
support its position, there can be no assurance as to the outcome
of the arbitration proceeding.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies2009 contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" xsi:nil="true" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;13. Commitments and
Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Product Development
Agreements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In June 2006,
PGP entered into an agreement with Watson Pharmaceuticals, Inc.
(together with its subsidiaries, &amp;#x201C;Watson&amp;#x201D;) under which
PGP acquired the rights to certain products under development
relating to transdermal delivery systems for testosterone for use
in females. Under the product development agreement, which the
Company acquired in connection with the PGP Acquisition, the
Company may be required to make additional payments to Watson upon
the achievement of various developmental milestones that could
aggregate up to $25,000. Further, the Company agreed to pay a
supply fee and royalties to Watson on the net sales of those
products, if any.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In July 2007,
the Company entered into an agreement with Paratek Pharmaceuticals
Inc. (&amp;#x201C;Paratek&amp;#x201D;) under which it acquired certain rights
to novel tetracyclines under development for the treatment of acne
and rosacea. The Company paid an up-front fee of $4,000 and agreed
to reimburse Paratek for R&amp;amp;D expenses incurred during the term
of the agreement. In September&amp;#xA0;2010, the Company made a $1,000
milestone payment to Paratek upon the achievement of a
developmental milestone. The Company may make additional payments
to Paratek upon the achievement of certain developmental milestones
that could aggregate up to $23,500. In addition, the Company agreed
to pay royalties to Paratek based on the net sales, if any, of the
products covered under the agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In December
2008, the Company signed an agreement (the &amp;#x201C;Dong-A
Agreement&amp;#x201D;) with Dong-A PharmTech Co. Ltd.
(&amp;#x201C;Dong-A&amp;#x201D;), to develop and, if approved, market its
orally-administered udenafil product, a PDE5 inhibitor, for the
treatment of erectile dysfunction (&amp;#x201C;ED&amp;#x201D;) in the United
States. The Company paid $2,000 in connection with signing the
Dong-A Agreement. In March 2009, the Company paid $9,000 to Dong-A
upon the achievement of a developmental milestone related to the ED
product under the Dong-A Agreement. The Company agreed to pay for
all development costs incurred during the term of the Dong-A
Agreement with respect to development of the ED product for the
United States and may make additional payments to Dong-A of up to
$13,000 upon the achievement of contractually-defined milestones in
relation to the ED product. In addition, the Company agreed to pay
a profit-split to Dong-A based on operating profit (as defined in
the Dong-A Agreement), if any, resulting from the commercial sale
of the ED product.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In
February&amp;#xA0;2009, the Company acquired the U.S. rights to Apricus
Biosciences, Inc.&amp;#x2019;s (formerly NexMed, Inc.)
(&amp;#x201C;Apricus&amp;#x201D;) topically applied alprostadil cream for the
treatment of ED and a prior license agreement between the Company
and Apricus relating to the product was terminated. Under the terms
of the acquisition agreement, the Company paid Apricus an up-front
payment of $2,500, and agreed to pay a milestone payment of $2,500
to Apricus upon the FDA&amp;#x2019;s approval of the product&amp;#x2019;s New
Drug Application. The Company is currently working to prepare its
response to the non-approvable letter that the FDA delivered to
Apricus in July 2008 with respect to the product.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In April 2010,
the Company amended the Dong-A Agreement to add the right to
develop, and if approved, market in the U.S. and Canada,
Dong-A&amp;#x2019;s udenafil product for the treatment of lower urinary
tract symptoms associated with Benign Prostatic Hyperplasia
(&amp;#x201C;BPH&amp;#x201D;). As a result of this amendment, the Company
made an up-front payment to Dong-A of $20,000 in April 2010. Under
the amendment, the Company may make additional payments to Dong-A
in an aggregate amount of up to $25,000 upon the achievement of
contractually-defined milestones in relation to the BPH product.
These payments would be in addition to the potential milestone
payments in relation to the ED product described above. The Company
also agreed to pay Dong-A a percentage of net sales of the BPH
product in the U.S. and Canada, if any.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In August 2010,
the Company and TaiGen Biotechnology Co. Ltd (&amp;#x201C;TaiGen&amp;#x201D;)
amended their existing license agreement in connection with the
completion of Phase II clinical trials to provide for the
cross-licensing of the parties&amp;#x2019; respective patent rights
relating to NEMONOXACIN and the transfer of TaiGen&amp;#x2019;s related
Investigational New Drug Application. Under the amended agreement,
TaiGen has exclusive development, manufacture and commercialization
rights in certain Asian countries, and the Company has development,
manufacture and commercialization rights in all other markets,
including the United States, Europe and Japan. As a result of the
amendment, the Company made an up-front payment to TaiGen of $5,000
in August 2010. Under the terms of the amended agreement, the
Company may make additional payments to TaiGen in an aggregate
amount of up to $25,000 upon the achievement of
contractually-defined milestones, and the Company also agreed to
pay TaiGen a royalty on its net sales of NEMONOXACIN, if
any.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company and
Sanofi are parties to the Collaboration Agreement pursuant to which
they co-promote ACTONEL on a global basis, excluding Japan.
ATELVIA, the Company&amp;#x2019;s next generation risedronate sodium
delayed-release product approved by the FDA in October 2010, is
also marketed in the United States pursuant to the Collaboration
Agreement. See &amp;#x201C;Note 7&amp;#x201D; for additional information
related to the Collaboration Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;18. Comprehensive
Income&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;ASC Topic 220,
&amp;#x201C;Comprehensive Income&amp;#x201D;, requires foreign currency
translation adjustments and certain other items, which were
reported in shareholders&amp;#x2019; (deficit) to be separately
disclosed as other comprehensive (loss). Other comprehensive income
/ (loss) is comprised of net income / (loss) plus the period
activity within accumulated other comprehensive income / (loss).
Other comprehensive (loss) was $(4,470) and ($28,925) for the
quarters ended March&amp;#xA0;31, 2011 and 2010,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The components
of accumulated other comprehensive income / (loss) consist
of:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="65%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;As&amp;#xA0;of&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;As&amp;#xA0;of&lt;br /&gt;
December&amp;#xA0;31,&amp;#xA0;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Cumulative translation
adjustment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(4,164&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(23,829&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Actuarial gains related to
defined benefit plans (net of tax)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;8,106&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;8,184&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;3,942&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(15,645&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">122911000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;11.
Indebtedness&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;New Senior Secured
Credit Facilities&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
March&amp;#xA0;17, 2011, Warner Chilcott Holdings Company III, Limited
(&amp;#x201C;Holdings III&amp;#x201D;), WC Luxco S.&amp;#xE0; r.l. (the
&amp;#x201C;Luxco Borrower&amp;#x201D;), Warner Chilcott Corporation
(&amp;#x201C;WCC&amp;#x201D; or the &amp;#x201C;US Borrower&amp;#x201D;) and WCCL (the
&amp;#x201C;PR Borrower&amp;#x201D;, and together with the Luxco Borrower and
the US Borrower, the &amp;#x201C;Borrowers&amp;#x201D;) entered into a new
credit agreement (the &amp;#x201C;Credit Agreement&amp;#x201D;) with a
syndicate of lenders (the &amp;#x201C;Lenders&amp;#x201D;) and Bank of
America, N.A. as administrative agent in order to refinance the
Company&amp;#x2019;s Prior Senior Secured Credit Facilities (as defined
below). Pursuant to the Credit Agreement, the Lenders provided
senior secured credit facilities (the &amp;#x201C;New Senior Secured
Credit Facilities&amp;#x201D;) in an aggregate amount of $3,250,000
comprised of (i)&amp;#xA0;$3,000,000 in aggregate term loan facilities
and (ii)&amp;#xA0;a $250,000 revolving credit facility available to all
Borrowers. The term loan facilities are comprised of (i)&amp;#xA0;a
$1,250,000 Term A Loan Facility (the &amp;#x201C;Term A Loan&amp;#x201D;) and
(ii)&amp;#xA0;a $1,750,000 Term B Loan Facility consisting of an
$800,000 Term B-1 Loan, a $400,000 Term B-2 Loan and a $550,000
Term B-3 Loan (together, the &amp;#x201C;Term B Loans&amp;#x201D;). The
proceeds of these new term loans, together with approximately
$279,000 of cash on hand, were used to repay $3,218,980 in
aggregate term loans outstanding under the Prior Senior Secured
Credit Facilities, terminate the Prior Senior Secured Credit
Facilities and pay certain related fees, expenses and accrued
interest.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Term A Loan
matures on March&amp;#xA0;17, 2016 and bears interest at LIBOR plus
3.00%, with a LIBOR floor of 0.75%, and each of the Term B Loans
matures on March&amp;#xA0;15, 2018 and bears interest at LIBOR plus
3.25%, with a LIBOR floor of 1.00%. The revolving credit facility
matures on March&amp;#xA0;17, 2016 and includes a $20,000 sublimit for
swing line loans and a $50,000 sublimit for the issuance of standby
letters of credit. Any swing line loans and letters of credit would
reduce the available commitment under the revolving credit facility
on a dollar-for-dollar basis. Loans drawn and letters of credit
issued under the revolving credit facility bear interest at LIBOR
plus 3.00%. The Borrowers are also required to pay a commitment fee
on the unused commitments under the revolving credit facility at a
rate of 0.75%&amp;#xA0;per annum, subject to a leverage-based
step-down.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The loans and
other obligations under the New Senior Secured Credit Facilities
(including in respect of hedging agreements and cash management
obligations) are (i)&amp;#xA0;guaranteed by Holdings III and
substantially all of its subsidiaries (subject to certain
exceptions and limitations) and (ii)&amp;#xA0;secured by substantially
all of the assets of the Borrowers and each guarantor (subject to
certain exceptions and limitations). As of March&amp;#xA0;31, 2011
there were letters of credit totaling $1,500 outstanding. As a
result the Company had $248,500 available under the revolving
credit facility as of March&amp;#xA0;31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The carrying
amounts reported in the condensed consolidated balance sheets as of
March&amp;#xA0;31, 2011 for the Company&amp;#x2019;s debt outstanding under
its New Senior Secured Credit Facilities approximates fair value as
interest is at variable rates and it re-prices
frequently.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Prior Senior Secured
Credit Facilities&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
October&amp;#xA0;30, 2009 in connection with the PGP Acquisition,
Holdings III and its subsidiaries, the Luxco Borrower, WCC and WCCL
entered into a credit agreement with Credit Suisse AG, Cayman
Islands Branch as administrative agent and lender, and the other
lenders and parties thereto pursuant to which the lenders provided
senior secured credit facilities in an aggregate amount of
$3,200,000 (the &amp;#x201C;Prior Senior Secured Credit
Facilities&amp;#x201D;). The Prior Senior Secured Credit Facilities
initially consisted of $2,950,000 of term loans, a $250,000
revolving credit facility and a $350,000 delayed-draw term loan
facility. On December&amp;#xA0;16, 2009, the Borrowers entered into an
amendment pursuant to which the Lenders agreed to provide
additional term loans of $350,000, and the delayed-draw term loan
facility was terminated. The additional term loans were used to
finance, together with cash on hand, the repurchase or redemption
of any and all of the Company&amp;#x2019;s then-outstanding 8.75% senior
subordinated notes due 2015. On August&amp;#xA0;20, 2010, Holdings III
and the Borrowers entered into a subsequent amendment pursuant to
which the Lenders provided additional term loans in an aggregate
principal amount of $1,500,000 which, together with the proceeds
from the issuance of $750,000 aggregate principal amount of the
Company&amp;#x2019;s 7.75% Notes (defined below), were used to fund a
special cash dividend to shareholders in the amount of $8.50 per
share, or $2,144,321 in the aggregate (the &amp;#x201C;Special
Dividend&amp;#x201D;) and to pay related fees and expenses. In January
2011, the Company made an optional prepayment of $200,000 of its
term loan indebtedness under the Prior Senior Secured Credit
Facilities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;7.75%
Notes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
August&amp;#xA0;20, 2010, the Company and certain of the
Company&amp;#x2019;s subsidiaries entered into an indenture (the
&amp;#x201C;Indenture&amp;#x201D;) with Wells Fargo Bank, National
Association, as trustee, in connection with the issuance by WCCL
and Warner Chilcott Finance LLC (together, the
&amp;#x201C;Issuers&amp;#x201D;) of $750,000 aggregate principal amount of
7.75% senior notes due 2018 (the &amp;#x201C;Initial 7.75%
Notes&amp;#x201D;). The Initial 7.75% Notes are unsecured senior
obligations of the Issuers, guaranteed on a senior basis by the
Company and its subsidiaries that guarantee obligations under the
New Senior Secured Credit Facilities, subject to certain
exceptions. The Initial 7.75% Notes will mature on
September&amp;#xA0;15, 2018. Interest on the Initial 7.75% Notes is
payable on March&amp;#xA0;15 and September&amp;#xA0;15 of each year, and
the first payment was made on March&amp;#xA0;15, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
September&amp;#xA0;29, 2010, the Issuers issued an additional $500,000
aggregate principal amount of 7.75% senior notes due 2018 at a
premium of $10,000 (the &amp;#x201C;Additional 7.75% Notes&amp;#x201D; and,
together with the Initial 7.75% Notes, the &amp;#x201C;7.75%
Notes&amp;#x201D;). The proceeds from the issuance of the Additional
7.75% Notes were used by the Company to fund its $400,000 upfront
payment in connection with the ENABLEX Acquisition, which closed on
October&amp;#xA0;18, 2010, and for general corporate purposes. The
Additional 7.75% Notes constitute a part of the same series as the
Initial 7.75% Notes. The Issuers&amp;#x2019; obligations under the
Additional 7.75% Notes are guaranteed by the Company and by its
subsidiaries that guarantee obligations under the New Senior
Secured Credit Facilities, subject to certain exceptions. The
$10,000 premium received was added to the face value of the 7.75%
Notes and is being amortized over the life of the 7.75% Notes as a
reduction to reported interest expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Indenture
contains restrictive covenants that limit, among other things, the
ability of Holdings III, and certain of Holdings III&amp;#x2019;s
subsidiaries, to incur additional indebtedness, pay dividends and
make distributions on common and preferred stock, repurchase
subordinated debt and common and preferred stock, make other
restricted payments, make investments, sell certain assets, incur
liens, consolidate, merge, sell or otherwise dispose of all or
substantially all of its assets and enter into certain transactions
with affiliates. The Indenture also contains customary events of
default which would permit the holders of the 7.75% Notes to
declare those 7.75% Notes to be immediately due and payable if not
cured within applicable grace periods, including the failure to
make timely payments on the 7.75% Notes or other material
indebtedness, the failure to satisfy covenants, and specified
events of bankruptcy and insolvency.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;As of
March&amp;#xA0;31, 2011, the fair value of the Company&amp;#x2019;s
outstanding 7.75% Notes, based on available market quotes, was
$1,309,375 ($1,250,000 book value).&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px; margin-left:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Components
of Indebtedness&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;As of
March&amp;#xA0;31, 2011, the Company&amp;#x2019;s outstanding debt included
the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="92%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="60%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Current&amp;#xA0;Portion&lt;br /&gt;
as of&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Long-Term&lt;br /&gt;
Portion as of&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Total&amp;#xA0;Outstanding&lt;br /&gt;
as of&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Revolving credit
facility&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Term loans under the New
Senior Secured Credit Facilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;142,500&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,857,500&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;3,000,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7.75% Notes (including
$9,368 unamortized premium)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,263&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,258,105&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,259,368&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;143,763&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,115,605&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,259,368&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;As of
March&amp;#xA0;31, 2011, mandatory principal repayments of long-term
debt for the remainder of 2011 and each of the five years ending
December&amp;#xA0;31, 2012 through 2016 and thereafter were as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="68%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="85%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;
&lt;p style="border-bottom:1px solid #000000;width:92pt"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Year Ending
December&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Aggregate&lt;br /&gt;
Maturities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;106,875&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;236,250&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;267,500&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;267,500&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;361,250&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;111,250&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,899,375&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total long-term debt to be
settled in cash&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,250,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7.75% Notes unamortized
premium&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;9,368&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total long-term
debt&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,259,368&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:Depreciation contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">10519000</us-gaap:Depreciation>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;12. Stock-Based
Compensation Plans&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The
Company&amp;#x2019;s stock-based compensation, including grants of
non-qualified time-based vesting options to purchase ordinary
shares and grants of time-based and performance-based vesting
restricted ordinary shares and their equivalents, is measured at
fair value on the date of grant and is recognized in the statement
of operations as compensation expense over the applicable vesting
periods. For purposes of computing the amount of stock-based
compensation attributable to time-based vesting options and
time-based vesting restricted ordinary shares (and their
equivalents) expensed in any period, the Company treats such equity
grants as serial grants with separate vesting dates. This treatment
results in accelerated recognition of share-based compensation
expense whereby 52% of the compensation is recognized in year one,
27% is recognized in year two, 15% is recognized in year three, and
6% is recognized in the final year of vesting. The Company treats
performance-based vesting restricted ordinary share grants as
vesting evenly over a four year vesting period, subject to the
achievement of annual performance targets.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Total
stock-based compensation expense recognized for the quarters ended
March&amp;#xA0;31, 2011 and 2010 was $5,576 and $4,683, respectively.
Unrecognized future stock-based compensation expense was $44,788 as
of March&amp;#xA0;31, 2011, which will be recognized as an expense over
a remaining weighted average period of 1.31 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In establishing
the value of the options on each grant date, the Company uses its
actual historical volatility for its ordinary shares to estimate
the expected volatility at each grant date. The fair value of
options is determined on the applicable grant date using the
Black-Scholes method of valuation and that amount is recognized as
an expense over the four year vesting period. The options have a
term of ten years. The Company assumes that the options will be
exercised, on average, in six years. The Special Dividend paid in
2010 did not impact the dividend yield assumption for any grants.
Using the Black-Scholes valuation model, the fair value of the
options is based on the following assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="74%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;2011&amp;#xA0;Grants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;2010&amp;#xA0;Grants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Dividend yield&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;None&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected
volatility&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;35.00&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;35.00&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Risk-free interest
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;3.57&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2.52&amp;#xA0;&amp;#x2013;&amp;#xA0;3.83&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;%&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected term
(years)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6.00&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6.00&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The weighted
average remaining contractual term of all outstanding options to
purchase ordinary shares granted is 7.2 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following is
a summary of equity award activity for unvested restricted ordinary
shares, and their equivalent, in the period from December&amp;#xA0;31,
2010 through March&amp;#xA0;31, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="84%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="78%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Restricted Share
Grants&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;(and their
equivalent)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;(in thousands except per
share amounts)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&amp;#xA0;Fair&lt;br /&gt;
Value&amp;#xA0;per&amp;#xA0;share&lt;br /&gt;
on&amp;#xA0;Grant&lt;br /&gt;
Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Unvested restricted
ordinary shares, and their equivalent, at December&amp;#xA0;31,
2010&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;918&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;19.91&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Granted shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,250&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;24.70&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Vested shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(263&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;18.70&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Forfeited shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(7&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;24.52&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Unvested restricted
ordinary shares, and their equivalent, at March&amp;#xA0;31,
2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,898&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;23.22&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following is
a summary of equity award activity for non-qualified options to
purchase ordinary shares in the period from December&amp;#xA0;31, 2010
through March&amp;#xA0;31, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="84%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="68%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="10" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Options to Purchase
Ordinary Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;(in thousands except per
option amounts)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&amp;#xA0;Fair&lt;br /&gt;
Value&amp;#xA0;per&amp;#xA0;Option&lt;br /&gt;
on&amp;#xA0;Grant&lt;br /&gt;
Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&amp;#xA0;per&lt;br /&gt;
Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Balance at
December&amp;#xA0;31, 2010&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,473&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5.57&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11.94&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Granted options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;596&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;10.11&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;25.01&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Exercised options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(204&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6.85&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;8.40&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Forfeited options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(26&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;8.29&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;12.93&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Balance at March&amp;#xA0;31,
2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,839&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5.87&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;13.02&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Vested and exercisable at
March&amp;#xA0;31, 2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,248&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;3.82&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11.69&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The intrinsic
value of non-qualified options to purchase ordinary shares is
calculated as the difference between the closing price of the
Company&amp;#x2019;s ordinary shares and the exercise price of the
non-qualified options to purchase ordinary shares that had a strike
price below the closing price. The total intrinsic value for the
non-qualified options to purchase ordinary shares that are
&amp;#x201C;in-the-money&amp;#x201D; as of March&amp;#xA0;31, 2011 was as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="92%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="63%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;(in thousands except per
share and per option amounts)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&amp;#xA0;per&lt;br /&gt;
Option&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Closing&lt;br /&gt;
Stock&lt;br /&gt;
Price&amp;#xA0;per&lt;br /&gt;
Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;br /&gt;
Intrinsic&lt;br /&gt;
Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Balance outstanding at
March&amp;#xA0;31, 2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,241&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;12.04&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;23.26&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;81,244&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Vested and exercisable at
March&amp;#xA0;31, 2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,248&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11.69&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;23.26&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;49,149&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;5. LEO
Transaction&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
September&amp;#xA0;23, 2009, the Company entered into a definitive
asset purchase agreement (the &amp;#x201C;LEO Transaction
Agreement&amp;#x201D;) with LEO Pharma A/S (&amp;#x201C;LEO&amp;#x201D;) pursuant
to which LEO paid the Company $1,000,000 in cash in order to
terminate the Company&amp;#x2019;s exclusive license to distribute
LEO&amp;#x2019;s DOVONEX and TACLONEX products (including all
dermatology products in LEO&amp;#x2019;s development pipeline) in the
United States and to acquire certain assets related to the
Company&amp;#x2019;s distribution of DOVONEX and TACLONEX products in
the United States (the &amp;#x201C;LEO Transaction&amp;#x201D;). The Company
recognized a gain on the sale of assets of $393,095 as a result of
the LEO Transaction. The LEO Transaction closed simultaneously with
the execution of the LEO Transaction Agreement. In connection with
the LEO Transaction, the Company entered into a distribution
agreement with LEO pursuant to which the Company agreed to, among
other things, (1)&amp;#xA0;continue to distribute DOVONEX and TACLONEX
on behalf of LEO, for a distribution fee, through
September&amp;#xA0;23, 2010 and (2)&amp;#xA0;purchase inventories of
DOVONEX and TACLONEX from LEO. In addition, the Company agreed to
provide certain transition services for LEO for a period of up to
one year after the closing. On June&amp;#xA0;30, 2010, LEO assumed
responsibility for its own distribution services and on
July&amp;#xA0;15, 2010 the parties formally terminated the distribution
agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;During the
quarter ended September&amp;#xA0;30, 2009, in connection with the
distribution agreement mentioned above, the Company recorded a
deferred gain of $68,919 relating to the sale of certain
inventories in connection with the LEO Transaction. Pursuant to
Financial Accounting Standards Board Accounting Standards
Codification (&amp;#x201C;ASC&amp;#x201D;) Sub Topic 605-25, &amp;#x201C;Revenue
Recognition&amp;#x2014;Multiple-Element Arrangements&amp;#x201D;, separate
contracts with the same entity that are entered into at or near the
same time are presumed to have been negotiated as a package and
should be evaluated as a single arrangement. The LEO Transaction
and distribution agreement contained (i)&amp;#xA0;multiple
deliverables, (ii)&amp;#xA0;a delivered element with stand-alone value
(intangible asset), and (iii)&amp;#xA0;objective and reliable evidence
of the undelivered item&amp;#x2019;s fair value. For the undelivered
element, inventory, the Company retained title and the risks and
rewards of ownership. The total arrangement consideration (or
purchase price) of $1,000,000 was allocated among the units of
accounting as set forth in ASC Sub Topic 605-25 &amp;#x201C;Revenue
Recognition&amp;#x2014;Multiple-Element Arrangements&amp;#x201D; paragraph
30-1, and the portion of the gain in the amount of $68,919 on the
undelivered product inventory at fair value, was deferred as of
September&amp;#xA0;30, 2009.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company
subsequently sold the inventory on behalf of LEO to its trade
customers in the normal course of business and recognized revenues
of approximately $76,762, $62,530 and $26,255, and cost of sales of
approximately $42,578, $37,419 and $16,631 during the quarters
ended December&amp;#xA0;31, 2009,&amp;#xA0;March&amp;#xA0;31, 2010 and
June&amp;#xA0;30, 2010, respectively. The amounts were recognized as
sales and cost of sales in the Company&amp;#x2019;s statement of
operations when the earnings process was culminated as the goods
were delivered to the Company&amp;#x2019;s trade customers.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.10</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.10</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;6. Earnings Per
Share&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company
accounts for earnings per share (&amp;#x201C;EPS&amp;#x201D;) in accordance
with ASC Topic&amp;#xA0;260, &amp;#x201C;Earnings Per Share&amp;#x201D; and
related guidance, which requires two calculations of EPS to be
disclosed: basic and diluted. The numerator in calculating basic
and diluted EPS is an amount equal to the consolidated net
income/(loss) for the periods presented. The denominator in
calculating basic EPS is the weighted average shares outstanding
for the respective periods. The denominator in calculating diluted
EPS is the weighted average shares outstanding, plus the dilutive
effect of stock option grants, restricted share grants and their
equivalent for the respective periods. The following sets forth the
basic and diluted calculations of EPS for the quarters ended
March&amp;#xA0;31, 2011 and 2010, respectively:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="92%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="74%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter Ended&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter Ended&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Net (loss) available to
ordinary shareholders&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(24,057&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(17,243&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Weighted average number of
ordinary and potential ordinary shares outstanding:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Basic number of ordinary
shares outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;251,945,687&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;251,003,407&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Dilutive effect of grants of
stock options, unvested restricted shares and their
equivalent&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Diluted number of ordinary
and potential ordinary shares outstanding&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;251,945,687&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;251,003,407&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(Loss) per ordinary
share:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Basic&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(0.07&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Diluted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(0.10&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(0.07&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Weighted-average amounts not
included in calculation of diluted EPS as their impact was
anti-dilutive under the treasury stock method:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Stock options to purchase
ordinary shares&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,836,781&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;8,035,816&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Unvested restricted shares
and equivalent&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,085,067&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,118,539&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">5903000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;9. Goodwill and
Intangible Assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The
Company&amp;#x2019;s goodwill and a trademark have been deemed to have
indefinite lives and are not amortized. The Company&amp;#x2019;s
acquired intellectual property, licensing agreements and certain
trademarks that do not have indefinite lives are being amortized on
either an economic benefit model, which typically results in
accelerated amortization, or a straight-line basis over their
useful lives not to exceed 15 years. Components of the
Company&amp;#x2019;s intangible assets as of March&amp;#xA0;31, 2011,
consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="84%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="61%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Gross&amp;#xA0;Carrying&lt;br /&gt;
Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Accumulated&lt;br /&gt;
Amortization&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Net&amp;#xA0;Carrying&lt;br /&gt;
Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Definite-lived intangible
assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ASACOL&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,848,702&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;339,557&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,509,145&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ENABLEX&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;505,731&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;68,209&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;437,522&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ACTONEL&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;525,205&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;250,541&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;274,664&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ATELVIA&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;241,447&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,206&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;240,241&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ESTRACE Cream&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;411,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;267,153&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;143,847&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;DORYX&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;331,300&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;197,980&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;133,320&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;OVCON / FEMCON FE product
family&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;401,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;380,270&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;20,730&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;FEMHRT product
family&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;318,500&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;306,599&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11,901&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other products intellectual
property&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;435,228&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;366,682&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;68,546&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Total Definite-lived
intangible assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5,018,113&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,178,197&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,839,916&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Indefinite-lived
intangible assets&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Trademark&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;30,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;30,000&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Total intangible assets,
net&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5,048,113&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,178,197&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,869,916&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Aggregate
amortization expense related to intangible assets was $147,645 and
$160,912 for the quarters ended March&amp;#xA0;31, 2011 and 2010,
respectively. The Company continuously reviews its products&amp;#x2019;
remaining useful lives based on each product&amp;#x2019;s estimated
future cash flows.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;As of
March&amp;#xA0;31, 2011 estimated amortization expense based on current
forecasts (excluding indefinite-lived intangible assets) for the
remainder of 2011 and for each of the next five years is as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="68%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="85%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Amortization&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;442,971&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2012&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;497,970&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2013&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;444,464&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2014&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;375,501&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2015&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;332,980&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2016&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;219,680&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Thereafter&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;526,350&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,839,916&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">3948000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;15. Income
Taxes&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company
operates in many tax jurisdictions including: the Republic of
Ireland, the United States, the United Kingdom, Puerto Rico,
Canada, Germany, Switzerland and other Western European countries.
The Company&amp;#x2019;s effective tax rate for the quarters ended
March&amp;#xA0;31, 2011 and 2010 was 709% and 58%, respectively. The
effective income tax rate for interim reporting periods is volatile
due to changes in income mix among the various tax jurisdictions in
which the Company operates, the impact of discrete items, as well
as the overall level of consolidated income before income taxes. In
the quarter ended March&amp;#xA0;31, 2011 the discrete items included
valuation allowances related to the announced restructuring of
certain of the Company&amp;#x2019;s Western European operations. The
Company&amp;#x2019;s estimated annual effective tax rate for all periods
includes the impact of changes in income tax liabilities related to
reserves recorded under ASC Topic 740.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">1271000</us-gaap:IncomeTaxesPaid>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">28005000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">6904000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;8.
Inventories&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Inventories
consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="66%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;As of&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#xA0;31,&amp;#xA0;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Finished goods&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;62,308&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;64,891&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Work-in-progress /
Bulk&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;31,110&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;27,602&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Raw materials&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;23,619&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;27,004&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;117,037&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;119,497&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Total
inventories above are net of $16,003 and $8,470 related to
inventory obsolescence reserves as of March&amp;#xA0;31, 2011 and
December&amp;#xA0;31, 2010, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Product samples
are stated at cost ($8,101 and $7,427 as of March&amp;#xA0;31, 2011 and
December&amp;#xA0;31, 2010, respectively) and were included in prepaid
expenses and other current assets.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-466808000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-12057000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">271822000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-24057000</us-gaap:NetIncomeLoss>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;1.
General&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The
accompanying unaudited interim condensed consolidated financial
statements have been prepared pursuant to the rules and regulations
for reporting on Form 10-Q. Accordingly, certain information and
disclosures required by accounting principles generally accepted in
the United States (&amp;#x201C;U.S. GAAP&amp;#x201D;) for complete
consolidated financial statements have been condensed or are not
included herein. The interim statements should be read in
conjunction with the audited consolidated financial statements and
notes thereto included in the Company&amp;#x2019;s Annual Report on Form
10-K for the year ended December&amp;#xA0;31, 2010 (the &amp;#x201C;Annual
Report&amp;#x201D;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The results of
operations of any interim period are not necessarily indicative of
the results of operations for the full year. The unaudited interim
condensed consolidated financial information presented herein
reflects all normal adjustments that are, in the opinion of
management, necessary for a fair statement of the financial
position, results of operations and cash flows for the periods
presented. The Company is responsible for the unaudited interim
condensed consolidated financial statements included in this
report. The Company has made certain reclassifications to prior
period information to conform to the current period presentation.
All intercompany transactions and balances have been eliminated in
consolidation.&lt;/font&gt;&lt;/p&gt;


&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherAssetImpairmentCharges contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">20889000</us-gaap:OtherAssetImpairmentCharges>
  <us-gaap:PaymentsOfFinancingCosts contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">50976000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">12057000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromBankDebt contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">3000000000</us-gaap:ProceedsFromBankDebt>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">1429000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">1719000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;20. Related
Parties&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In March 2011,
certain of the Company&amp;#x2019;s shareholders sold approximately
26,500,000 ordinary shares at a price of $23.25 per share in a
registered public offering (the &amp;#x201C;2011 Secondary
Offering&amp;#x201D;). The selling shareholders included the remaining
sponsors and members of the Company&amp;#x2019;s senior management team.
The Company did not receive any proceeds from the sale of the
shares but did pay expenses of the 2011 Secondary Offering.
Following the 2011 Secondary Offering, the remaining sponsors
collectively owned approximately 30% of the Company&amp;#x2019;s
ordinary shares.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">30914000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;3. Strategic
Initiatives&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Western European
Restructuring&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2011,
the Company announced a plan to restructure its operations in
Belgium, the Netherlands, France, Germany, Italy, Spain,
Switzerland and the United Kingdom. The restructuring will not
impact the Company&amp;#x2019;s operations at its headquarters in
Dublin, Ireland, its facilities in Dundalk, Ireland, Larne,
Northern Ireland or Weiterstadt, Germany or its commercial
operations in the United Kingdom. The Company determined to proceed
with the restructuring following the completion of a strategic
review of its operations in its Western European markets where its
product ACTONEL lost exclusivity in late 2010. ACTONEL accounted
for approximately 70% of the Company&amp;#x2019;s Western European
revenues in the year ended December 31, 2010. In connection with
the restructuring, the Company intends to move to a wholesale
distribution model in the affected jurisdictions to minimize
operational costs going forward. The Company currently expects to
complete the restructuring by the middle of 2012. The
implementation of the restructuring plan, which is expected to
impact approximately 500 employees, and the aggregate amounts to be
expensed, remain subject to consultation with local works councils
in certain European jurisdictions. Severance costs of $42,919 were
recorded in the quarter ended March 31, 2011 and were included as a
component of restructuring costs in the condensed consolidated
statement of operations. Severance related costs are expected to be
settled in cash within the next twelve months. The Western European
restructuring costs were recorded in the Company&amp;#x2019;s ROW
operating segment (as defined in &amp;#x201C;Note 16&amp;#x201D;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Manati
Facility&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In April 2011,
the Company announced a plan to repurpose its Manati, Puerto Rico
manufacturing facility. Going forward this facility will serve as a
warehouse and distribution center. As a result of the repurposing,
the Company recorded a charge of $20,889 in the quarter ended March
31, 2011 for the write-down of certain property, plant and
equipment. Additionally, severance costs of $6,743 were recorded in
the quarter ended March 31, 2011. The severance costs relating to
the Manati repurposing are expected to be settled in cash within
the next twelve months. The expenses related to the Manati
repurposing were recorded in the Company&amp;#x2019;s North American
operating segment (as defined in &amp;#x201C;Note 16&amp;#x201D;) as a
component of cost of sales.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
table summarizes the activity in the Company&amp;#x2019;s severance
accruals during the quarter ended March 31, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
&lt;tr&gt;
&lt;td width="88%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Balance, December 31,
2010&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;5,975&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Severance charges for newly
identified employees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;49,662&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;633&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Cash payments during the
period&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;(941&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 1px solid" valign="bottom"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Balance, March 31,
2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;55,329&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" nowrap="nowrap"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="FONT-SIZE: 1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-TOP: #000000 3px double" valign="bottom"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;


&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:RestructuringCharges contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">42919000</us-gaap:RestructuringCharges>
  <us-gaap:Revenues contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">756529000</us-gaap:Revenues>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">25782000</us-gaap:RoyaltyRevenue>
  <us-gaap:SalesRevenueNet contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">730747000</us-gaap:SalesRevenueNet>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;16. Segment
Information&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The
Company&amp;#x2019;s business is organized into two reportable segments,
North America (which includes the U.S., Canada and Puerto Rico) and
the Rest of the World (&amp;#x201C;ROW&amp;#x201D;) consistent with how it
manages its business and views the markets it serves. The Company
manages its businesses separately in North America and ROW as
components of an enterprise for which separate information is
available that is evaluated regularly by the chief operating
decision maker in deciding how to allocate resources and assess
performance. In addition to managing the Company&amp;#x2019;s results of
operations in the two reportable segments, the Company manages
revenues at a brand level.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;An operating
segment&amp;#x2019;s performance is primarily evaluated based on segment
operating profit, which excludes interest expense, and is used by
the chief operating decision maker to evaluate the success of a
specific region. The Company believes that segment operating profit
is an appropriate measure for evaluating the operating performance
of its segments. However, this measure should be considered in
addition to, not a substitute for, or superior to, income from
operations or other measures of financial performance prepared in
accordance with U.S. GAAP.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
represents the Company&amp;#x2019;s segment operating profit and a
reconciliation to its consolidated income before taxes for the
quarters ended March&amp;#xA0;31, 2011 and 2010:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="92%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="57%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;North&lt;br /&gt;
America&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;ROW&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Eliminations(1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Total&lt;br /&gt;
Company&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Quarter Ended
March&amp;#xA0;31, 2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,323,362&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;203,372&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(770,205&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;756,529&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Segment operating
profit&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;426,141&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;9,523&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(274,926&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;160,738&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Corporate
expenses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(1,765&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Interest (expense),
net&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(155,025&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Income before
taxes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;3,948&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Quarter Ended
March&amp;#xA0;31, 2010&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total revenue&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;794,768&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;209,825&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(243,291&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;761,302&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Segment operating
profit&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;64,292&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;35,345&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(62,043&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;37,594&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Corporate
expenses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(5,845&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Interest (expense),
net&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(72,398&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(Loss) before
taxes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(40,649&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(1)&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Eliminations represent
inter-segment revenues and related cost of sales.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
table presents total revenues by product for the quarters ended
March&amp;#xA0;31, 2011 and 2010:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="70%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter
Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter&amp;#xA0;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0; 2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Revenue breakdown by
product&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ACTONEL&lt;/font&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;sup style="vertical-align:baseline; position:relative; bottom:.8ex"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;231,651&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;262,308&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ASACOL&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;187,327&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;165,020&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;LOESTRIN 24 FE&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;119,272&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;78,751&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;DORYX&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;65,928&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;50,900&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ENABLEX&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;45,304&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;18,180&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ESTRACE Cream&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;34,553&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;29,758&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;LO LOESTRIN FE&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,958&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;FEMHRT&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,890&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;9,293&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;FEMCON FE&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6,080&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;10,636&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ATELVIA&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;975&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;DOVONEX&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;37,804&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;TACLONEX&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;34,906&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other Women&amp;#x2019;s
Healthcare&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;15,646&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;15,892&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other Hormone
Therapy&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6,368&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,398&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other Oral
Contraceptives&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,049&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,432&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other products&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;17,120&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;20,815&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Contract manufacturing
product sales&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,902&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5,129&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other revenue&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;3,506&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,080&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Total
revenue&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;756,529&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;761,302&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;(1)&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;Other revenue related to
ACTONEL is combined with its product net sales for purposes of
presenting revenue by product and segment reporting.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
tables present additional segment information for the quarters
ended March&amp;#xA0;31, 2011 and 2010:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="84%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="65%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;North&amp;#xA0;America&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;ROW&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Total&amp;#xA0;Company&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Quarter ended
March&amp;#xA0;31, 2011&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Capital
expenditures&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,961&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,096&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;12,057&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Amortization of intangible
assets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;146,250&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,395&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;147,645&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Depreciation
expense&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6,740&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;3,779&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;10,519&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Write-down of property,
plant and equipment&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;20,889&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;20,889&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td height="8"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;td height="8" colspan="4"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Quarter ended
March&amp;#xA0;31, 2010&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Capital
expenditures&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;10,115&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5,347&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;15,462&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Amortization of intangible
assets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;137,212&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;23,700&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;160,912&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Depreciation
expense&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6,044&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,447&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,491&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
table presents total revenue by significant country of domicile for
the quarters ended March&amp;#xA0;31, 2011 and 2010:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="70%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter
Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter
Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;U.S.&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;618,811&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;562,386&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;France&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;31,490&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;40,393&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Canada&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;21,067&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;40,557&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Puerto Rico&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;13,139&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,817&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;UK / Republic of
Ireland&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;12,740&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;24,993&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Italy&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;12,487&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;17,220&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;46,795&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;67,936&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;756,529&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;761,302&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">253167000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">5576000</us-gaap:ShareBasedCompensation>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;2. Summary of
Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The following
are interim updates to certain of the policies described in
&amp;#x201C;Note 2&amp;#x201D; of the notes to the Company&amp;#x2019;s audited
consolidated financial statements for the year ended
December&amp;#xA0;31, 2010 included in the Annual Report.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Revenue
Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Revenue from
product sales is recognized when title and risk of loss to the
product transfers to the customer, which is based on the
transaction shipping terms. Product sales are recorded net of all
sales-related deductions including, but not limited to: trade
discounts, sales returns, commercial and government rebates,
customer loyalty programs and fee for service arrangements with
certain distributors. The Company establishes accruals for its
sales-related deductions in the same period that it recognizes the
related gross sales based on select criteria for estimating such
contra revenues including, but not limited to: estimated
utilization or redemption rates, contract terms, costs related to
the programs and other historical data. These reserves reduce
revenues and are included as either a reduction of accounts
receivable or as a component of accrued expenses. No revisions were
made to the methodology used in determining these reserves during
the quarter ended March&amp;#xA0;31, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;As of
March&amp;#xA0;31, 2011 and December&amp;#xA0;31, 2010, the amounts related
to all sales-related deductions included as a reduction of accounts
receivable were $29,240 and $30,274, respectively. The amounts
included in accrued liabilities were $438,833 and $455,041 (of
which $131,965 and $129,621 related to reserves for product
returns) as of March&amp;#xA0;31, 2011 and December&amp;#xA0;31, 2010,
respectively. The provisions recorded to reduce gross sales to net
sales were $202,971 and $218,417 in the quarters ended
March&amp;#xA0;31, 2011 and 2010, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Total other
revenue for the quarters ended March&amp;#xA0;31, 2011 and 2010 was
$25,782 and $51,846, respectively. Primarily as a result of the
ENABLEX Acquisition (as defined in &amp;#x201C;Note 4&amp;#x201D;), the
Company expects other revenue to decline in 2011 and product net
sales to increase with respect to ENABLEX, as compared to the prior
year period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Deferred Loan
Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;Expenses
associated with the issuance of indebtedness are capitalized and
amortized as a component of interest expense over the term of the
respective financing arrangements using the effective interest
method. In the event that long-term debt is prepaid, the deferred
loan costs associated with such indebtedness are expensed as a
component of interest expense in the period in which such
prepayment is made. Interest expense resulting from the
amortization and write-offs of deferred loan costs amounted to
$85,350 and $27,512 for the quarters ended March&amp;#xA0;31, 2011 and
2010, respectively. The increase in the quarter ended
March&amp;#xA0;31, 2011 compared to the prior year quarter was due
primarily to the write-offs of deferred loan costs in connection
with the termination of the Company&amp;#x2019;s Prior Senior Secured
Credit Facilities (as defined in &amp;#x201C;Note 11&amp;#x201D;). During the
quarter ended March&amp;#xA0;31, 2011, the Company paid $50,976 in
connection with the incurrence of new indebtedness under its New
Senior Secured Credit Facilities, as further discussed in
&amp;#x201C;Note 11&amp;#x201D;. Aggregate deferred loan costs were $124,872
and $159,188 as of March&amp;#xA0;31, 2011 and December&amp;#xA0;31, 2010,
respectively, and were included in other non-current assets in the
condensed consolidated balance sheet.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Restructuring
Costs&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company
records liabilities for costs associated with exit or disposal
activities in the period in which the liability is incurred. In
accordance with existing benefit arrangements, employee severance
costs are accrued when the restructuring actions are probable and
estimable. Costs for one-time termination benefits in which the
employee is required to render service until termination in order
to receive the benefits are recognized ratably over the future
service period. See &amp;#x201C;Note 3&amp;#x201D; for more
information.&lt;/font&gt;&lt;/p&gt;


&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <wcrx:IncreaseDecreaseInIncomeTaxesAndOtherNet contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">34080000</wcrx:IncreaseDecreaseInIncomeTaxesAndOtherNet>
  <wcrx:LegalProceedingsTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;14. Legal
Proceedings&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;General
Matters&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company is
involved in various legal proceedings in the normal course of its
business, including product liability litigation, intellectual
property litigation, employment litigation, such as unfair
dismissal and federal and state fair labor and minimum wage law
suits, and other litigation. The outcome of such litigation is
uncertain, and the Company may from time to time enter into
settlements to resolve such litigation, such as its settlement with
respect to FEMCON FE, that could result, among other things, in the
sale of generic versions of the Company&amp;#x2019;s products prior to
the expiration of its patents. For a description of the
Company&amp;#x2019;s settlement agreements, see the Company&amp;#x2019;s
Annual Report filed on February&amp;#xA0;25, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company
records reserves related to legal matters when losses related to
such litigation or contingencies are both probable and reasonably
estimable. The Company maintains insurance with respect to
potential litigation in the normal course of its business based on
its consultation with its insurance consultants and outside legal
counsel, and in light of current market conditions, including cost
and availability. In addition, the Company self-insures for certain
liabilities not covered under its litigation insurance based on
estimates of potential claims developed in consultation with its
insurance consultants and outside legal counsel.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
discussion is limited to the Company&amp;#x2019;s material on-going
legal proceedings:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Hormone Therapy
Product Liability Litigation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Approximately
721 product liability suits, including some with multiple
plaintiffs, have been filed against, or tendered to, the Company
related to its hormone therapy (&amp;#x201C;HT&amp;#x201D;) products, FEMHRT,
ESTRACE, ESTRACE Cream and medroxyprogesterone acetate. Under the
purchase and sale agreement pursuant to which the Company acquired
FEMHRT from Pfizer Inc. (&amp;#x201C;Pfizer&amp;#x201D;) in 2003, the Company
agreed to assume certain product liability exposure with respect to
claims made against Pfizer after March&amp;#xA0;5, 2003 and tendered to
the Company relating to FEMHRT products. The cases are in the early
stages of litigation and the Company is in the process of analyzing
and investigating the individual complaints.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The lawsuits
were likely triggered by the July 2002 and March 2004 announcements
by the National Institute of Health (&amp;#x201C;NIH&amp;#x201D;) of the
terminations of two large-scale randomized controlled clinical
trials, which were part of the Women&amp;#x2019;s Health Initiative
(&amp;#x201C;WHI&amp;#x201D;), examining the long-term effect of HT on the
prevention of coronary heart disease and osteoporotic fractures,
and any associated risk for breast cancer in postmenopausal women.
In the case of the trial terminated in 2002, which examined
combined estrogen and progestogen therapy (the &amp;#x201C;E&amp;amp;P Arm
of the WHI Study&amp;#x201D;), the safety monitoring board determined
that the risks of long-term estrogen and progestogen therapy
exceeded the benefits, when compared to a placebo. WHI
investigators found that combined estrogen and progestogen therapy
did not prevent heart disease in the study subjects and, despite a
decrease in the incidence of hip fracture and colorectal cancer,
there was an increased risk of invasive breast cancer, coronary
heart disease, stroke, blood clots and dementia. In the trial
terminated in 2004, which examined estrogen therapy, the trial was
ended one year early because the NIH did not believe that the
results were likely to change in the time remaining in the trial
and that the increased risk of stroke could not be justified for
the additional data that could be collected in the remaining time.
As in the E&amp;amp;P Arm of the WHI study, WHI investigators again
found that estrogen only therapy did not prevent heart disease and,
although study subjects experienced fewer hip fractures and no
increase in the incidence of breast cancer compared to subjects
randomized to placebo, there was an increased incidence of stroke
and blood clots in the legs. The estrogen used in the WHI Study was
conjugated equine estrogen and the progestin was
medroxyprogesterone acetate, the compounds found in Premarin
&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;sup style="vertical-align:baseline; position:relative; bottom:.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
and Prempro &lt;font style="font-family:Times New Roman" size="1"&gt;&lt;sup style="vertical-align:baseline; position:relative; bottom:.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;
, products marketed by Wyeth (now a part of Pfizer). Numerous
lawsuits were filed against Wyeth, as well as against other
manufacturers of HT products, after the publication of the summary
of the principal results of the E&amp;amp;P Arm of the WHI
Study.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Approximately
80% of the complaints filed against, or tendered to, the Company
did not specify the HT drug alleged to have caused the
plaintiff&amp;#x2019;s injuries. These complaints broadly allege that
the plaintiff suffered injury as a result of an HT product. The
Company has sought the dismissal of lawsuits that, after further
investigation, do not involve any of its products. The Company has
successfully reduced the number of HT suits it will have to defend.
Of the approximately 721 suits that were filed against, or tendered
to, the Company, 486 have been dismissed and 94 involving ESTRACE
have been successfully tendered to Bristol-Myers pursuant to an
indemnification provision in the asset purchase agreement pursuant
to which the Company acquired ESTRACE. The purchase agreement
included an indemnification agreement whereby Bristol-Myers
indemnified the Company for product liability exposure associated
with ESTRACE products that were shipped prior to July 2001. The
Company has forwarded agreed upon dismissal notices in another 13
cases to plaintiffs&amp;#x2019; counsel. Although it is impossible to
predict with certainty the outcome of any litigation, an
unfavorable outcome in these proceedings is not anticipated. An
estimate of the range of potential loss, if any, to the Company
relating to these proceedings is not possible at this
time.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;ACTONEL Product
Liability Litigation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company is a
defendant in approximately 97 cases and a potential defendant with
respect to approximately 67 unfiled claims involving a total of
approximately 171 plaintiffs and potential plaintiffs relating to
the Company&amp;#x2019;s bisphosphonate prescription drug ACTONEL. The
claimants allege, among other things, that ACTONEL caused them to
suffer osteonecrosis of the jaw (&amp;#x201C;ONJ&amp;#x201D;), a rare but
serious condition that involves severe loss or destruction of the
jawbone, and/or atypical fractures of the femur. All of the cases
have been filed in either federal or state courts in the United
States. The Company is in the initial stages of discovery in these
litigations. The 67 unfiled claims involve potential plaintiffs
that have agreed, pursuant to a tolling agreement, to postpone the
filing of their claims against the Company in exchange for the
Company&amp;#x2019;s agreement to suspend the statutes of limitations
relating to their potential claims. In addition, the Company is
aware of four&amp;#xA0;purported product liability&amp;#xA0;class
actions&amp;#xA0;that were brought against the Company in provincial
courts in Canada alleging, among other things, that ACTONEL caused
the plaintiffs&amp;#xA0;and the proposed class members who ingested
ACTONEL to suffer atypical fractures or other side effects. It is
expected&amp;#xA0;that these plaintiffs&amp;#xA0;will seek&amp;#xA0;class
certification. The Company is reviewing these lawsuits and
potential claims and intends to defend these claims
vigorously.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Sanofi, which
co-promotes ACTONEL with the Company on a global basis pursuant to
the Collaboration Agreement, is a defendant in many of the
Company&amp;#x2019;s ACTONEL product liability cases. In some of the
cases, manufacturers of other bisphosphonate products are also
named as defendants. Plaintiffs have typically asked for
unspecified monetary and injunctive relief, as well as
attorney&amp;#x2019;s fees. The Company cannot at this time predict the
outcome of these lawsuits and claims or their financial impact.
Under the Collaboration Agreement, Sanofi has agreed to indemnify
the Company, subject to certain limitations, for 50% of the losses
from any product liability claims in Canada relating to ACTONEL and
for 50% of the losses from any product liability claims in the U.S.
and Puerto Rico relating to ACTONEL brought prior to April&amp;#xA0;1,
2010, which would include ONJ-related claims that were pending as
of March&amp;#xA0;31, 2010. Pursuant to the April 2010 amendment to the
Collaboration Agreement, the Company will be fully responsible for
any product liability claims in the U.S. and Puerto Rico relating
to ACTONEL brought on or after April&amp;#xA0;1, 2010. The Company may
be liable for product liability, warranty or similar claims in
relation to PGP products, including ONJ-related claims that were
pending as of the closing of the PGP Acquisition. The
Company&amp;#x2019;s agreement with P&amp;amp;G provides that P&amp;amp;G will
indemnify the Company for 50% of the Company&amp;#x2019;s losses from
any such claims pending as of October&amp;#xA0;30, 2009, subject to
certain limits.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company
currently maintains product liability insurance coverage for claims
between $25 million and $170 million, subject to certain
exclusions, and otherwise is self-insured. The Company&amp;#x2019;s
insurance may not apply to, among other things, damages or defense
costs related to the above mentioned HT or ACTONEL-related claims,
including any claim arising out of HT or ACTONEL products with
labeling that does not conform completely to FDA approved labeling.
Although it is impossible to predict with certainty the outcome of
any litigation, an unfavorable outcome in these proceedings is not
anticipated. An estimate of the range of potential loss, if any, to
the Company relating to these proceedings is not possible at this
time.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;ASACOL 400 mg Patent
Matters&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In September
2007, PGP and Medeva Pharma Suisse AG (&amp;#x201C;Medeva&amp;#x201D;)
received a Paragraph IV certification notice letter from Roxane
Laboratories, Inc. (&amp;#x201C;Roxane&amp;#x201D;), a subsidiary of
Boehringher Ingelheim Corporation, indicating that Roxane had
submitted to the FDA an Abbreviated New Drug Application
(&amp;#x201C;ANDA&amp;#x201D;) seeking approval to manufacture and sell a
generic version of PGP&amp;#x2019;s ASACOL 400 mg product (&amp;#x201C;ASACOL
400&amp;#x201D;). The notice letter contended that Medeva&amp;#x2019;s U.S.
Patent No.&amp;#xA0;5,541,170 (the &amp;#x201C;&amp;#x2018;170 Patent&amp;#x201D;) and
U.S. Patent No.&amp;#xA0;5,541,171 (the &amp;#x201C;&amp;#x2018;171
Patent&amp;#x201D;), formulation and method patents which PGP
exclusively licenses from Medeva covering ASACOL 400, were invalid
and not infringed. The &amp;#x2018;170 Patent and &amp;#x2018;171 Patent
expire in July 2013. In October 2007, Medeva and PGP filed a patent
lawsuit against Roxane in the U.S. District Court for the District
of New Jersey alleging infringement of the &amp;#x2018;170 Patent. The
Company has elected not to bring an infringement action with
respect to the &amp;#x2018;171 Patent. The lawsuit resulted in a
30-month stay of FDA approval of Roxane&amp;#x2019;s ANDA until March
2010. The trial has been scheduled for July 2011. In addition,
Roxane has agreed not to launch a generic version of ASACOL 400
before September&amp;#xA0;30, 2011. While the Company and Medeva intend
to vigorously defend the &amp;#x2018;170 Patent and pursue their legal
rights, the Company can offer no assurance as to when the lawsuit
will be decided, whether the lawsuit will be successful or that a
generic equivalent of ASACOL 400 will not be approved and enter the
market prior to the expiration of the &amp;#x2018;170 Patent in
2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In
June&amp;#xA0;2010, the Company and Medeva received a Paragraph IV
certification notice letter from Par Pharmaceutical, Inc.
(&amp;#x201C;Par&amp;#x201D;) indicating that Par had submitted to the FDA an
ANDA seeking approval to manufacture and sell a generic version of
ASACOL 400. The notice letter contended that the &amp;#x2018;170 Patent
and &amp;#x2018;171 Patent were invalid and not infringed. In August
2010, the Company and Medeva filed a patent lawsuit against Par and
EMET Pharmaceuticals LLC (&amp;#x201C;EMET&amp;#x201D;) in the U.S. District
Court for the District of New Jersey alleging infringement of the
&amp;#x2018;170 Patent. The Company has elected not to bring an
infringement action with respect to the &amp;#x2018;171 Patent. EMET was
the original filer of the ANDA according to Par&amp;#x2019;s notice
letter, and assigned and transferred all right, title and interest
in the ANDA to Par in June 2010. The lawsuit resulted in a stay of
FDA approval of Par&amp;#x2019;s ANDA until December 2012, subject to
prior resolution of the matter before the court. While the Company
and Medeva intend to vigorously defend the &amp;#x2018;170 Patent and
pursue their legal rights, the Company can offer no assurance as to
when the lawsuit will be decided, whether the lawsuit will be
successful or that a generic equivalent of ASACOL 400 will not be
approved and enter the market prior to the expiration of the
&amp;#x2018;170 Patent in 2013.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;ACTONEL Patent
Matters&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In July 2004,
PGP received a Paragraph IV certification notice letter from a
subsidiary of Teva Pharmaceutical Industries, Ltd. (together with
its subsidiaries &amp;#x201C;Teva&amp;#x201D;) indicating that Teva had
submitted to the FDA an ANDA seeking approval to manufacture and
sell a generic version of PGP&amp;#x2019;s ACTONEL product. The notice
letter contended that PGP&amp;#x2019;s U.S. Patent No.&amp;#xA0;5,583,122
(the &amp;#x201C;&amp;#x2018;122 Patent&amp;#x201D;), a new chemical entity patent
expiring in June 2014 (including a 6-month pediatric extension of
regulatory exclusivity), was invalid, unenforceable or not
infringed. In August 2004, PGP filed a patent lawsuit against Teva
in the U.S. District Court for the District of Delaware charging
Teva with infringement of the &amp;#x2018;122 Patent. In January 2006,
Teva admitted patent infringement but alleged that the &amp;#x2018;122
Patent was invalid and, in February 2008, the District Court
decided in favor of PGP and upheld the &amp;#x2018;122 Patent as valid
and enforceable. In May 2009, the U.S. Court of Appeals for the
Federal Circuit unanimously upheld the decision of the District
Court.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In August
2008,&amp;#xA0;December 2008 and January 2009, PGP and Hoffman-La Roche
Inc. (&amp;#x201C;Roche&amp;#x201D;) received Paragraph IV certification
notice letters from Teva, Sun Pharma Global, Inc.
(&amp;#x201C;Sun&amp;#x201D;) and Apotex Inc. and Apotex Corp. (together
&amp;#x201C;Apotex&amp;#x201D;) indicating that each such company had
submitted to the FDA an ANDA seeking approval to manufacture and
sell generic versions of the once-a-month ACTONEL product
(&amp;#x201C;ACTONEL OaM&amp;#x201D;). The notice letters contended that
Roche&amp;#x2019;s U.S. Patent No.&amp;#xA0;7,192,938 (the &amp;#x201C;&amp;#x2018;938
Patent&amp;#x201D;), a method patent expiring in November 2023
(including a 6-month pediatric extension of regulatory exclusivity)
which Roche licensed to PGP with respect to ACTONEL OaM, was
invalid, unenforceable or not infringed. PGP and Roche filed patent
infringement suits against Teva (which delivered the first
Paragraph IV certification notice letter) in September 2008, Sun in
January 2009 and Apotex in March 2009 in the U.S. District Court
for the District of Delaware charging each with infringement of the
&amp;#x2018;938 Patent. The lawsuits result in a stay of FDA approval of
each defendant&amp;#x2019;s ANDA for 30 months from the date of
PGP&amp;#x2019;s and Roche&amp;#x2019;s receipt of notice, subject to the
prior resolution of the matters before the court. The stay of
approval of Teva&amp;#x2019;s ANDA has expired. ACTONEL OaM had FDA
exclusivity through April 2011 and the underlying &amp;#x2018;122
Patent, which covers all of the Company&amp;#x2019;s ACTONEL products,
expires in June 2014 (including a 6-month pediatric extension of
regulatory exclusivity).&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
December&amp;#xA0;1, 2009, the Company received a Paragraph IV
certification notice letter from Aurobindo Pharma Limited
(&amp;#x201C;Aurobindo&amp;#x201D;) regarding the Company&amp;#x2019;s ACTONEL 5,
30 and 35 mg dosage strength tablets (&amp;#x201C;ACTONEL
Tablets&amp;#x201D;), which are covered by the Company&amp;#x2019;s U.S.
Patent No.&amp;#xA0;6,165,513 (the &amp;#x201C;&amp;#x2018;513 Patent&amp;#x201D;), as
well as U.S. Patent Nos. 5,994,329, 6,015,801, 6,432,932 and
6,465,443, owned by Merck&amp;#xA0;&amp;amp; Co., Inc.
(&amp;#x201C;Merck&amp;#x201D;) and licensed by the Company (the &amp;#x201C;Merck
Patents&amp;#x201D;). The Paragraph IV certification notice letter
advised the Company of the filing of an ANDA with the FDA
requesting approval to manufacture and sell a generic version of
ACTONEL Tablets prior to the expiration of the &amp;#x2018;513 Patent in
2018 and the Merck Patents in 2019. Merck did not assert the Merck
Patents in any of the prior ACTONEL patent litigation. The Company
has elected not to bring an infringement action with respect to
this ANDA. In addition, Aurobindo did not certify against the
&amp;#x2018;122 Patent, which expires in June 2014 (including a 6-month
pediatric extension of regulatory exclusivity) and covers all of
the Company&amp;#x2019;s ACTONEL products (including the ACTONEL
Tablets). As a result, the Company does not believe that Aurobindo
will be permitted to market its proposed ANDA product prior to the
expiration of Teva&amp;#x2019;s 180-day period of marketing exclusivity
following the June 2014 expiration (including a 6-month pediatric
extension of regulatory exclusivity) of the &amp;#x2018;122
Patent.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In February 2010
and June 2010, the Company received Paragraph IV certification
notice letters from Mylan Pharmaceuticals Inc.
(&amp;#x201C;Mylan&amp;#x201D;) and Aurobindo, respectively, regarding the
Company&amp;#x2019;s ACTONEL with Calcium Tablets (Copackaged)
(&amp;#x201C;ACTONEL/Calcium&amp;#x201D;), which are covered by the
Company&amp;#x2019;s &amp;#x2018;513 Patent, as well as the Merck Patents
owned by Merck and licensed by the Company. Each of the Paragraph
IV certification letters advised the Company of the filing of an
ANDA with the FDA requesting approval to manufacture and sell a
generic version of ACTONEL/Calcium prior to the expiration of the
&amp;#x2018;513 Patent in 2018 and the Merck Patents in 2019. The
certification notice letters set forth allegations of
non-infringement and/or the invalidity of the &amp;#x2018;513 and Merck
Patents. Merck did not assert the Merck Patents in any of the prior
ACTONEL patent litigation. The Company previously discontinued
sales of ACTONEL/Calcium in the U.S. and has elected not to bring
infringement actions with respect to either of these ANDAs. In
addition, neither Mylan nor Aurobindo certified against the
&amp;#x2018;122 Patent which expires in June 2014 (including a 6-month
pediatric extension of regulatory exclusivity) and covers all of
the Company&amp;#x2019;s ACTONEL products (including ACTONEL/Calcium).
As a result, the Company does not believe that Mylan and Aurobindo
will be permitted to market their proposed ANDA products prior to
the expiration of Teva&amp;#x2019;s 180-day period of marketing
exclusivity following the June 2014 expiration (including a 6-month
pediatric extension of regulatory exclusivity) of the &amp;#x2018;122
Patent.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
February&amp;#xA0;24, 2010, the Company and Roche received a Paragraph
IV certification notice letter from Mylan indicating that it had
submitted to the FDA an ANDA seeking approval to manufacture and
sell generic versions of the Company&amp;#x2019;s 5, 30, 35 and 75 mg
dosage strength ACTONEL tablets, as well as ACTONEL OaM tablets.
The notice letter contends that the &amp;#x2018;513 Patent, the Merck
Patents and the &amp;#x2018;938 Patent which cover the products are
invalid and/or will not be infringed. The Company and Roche filed a
patent suit against Mylan in April 2010 in the U.S. District Court
for the District of Delaware charging Mylan with infringement of
the &amp;#x2018;938 Patent based on its proposed generic version of
ACTONEL OaM tablets. The lawsuit results in a stay of FDA approval
of Mylan&amp;#x2019;s ANDA for 30 months from the date of the
Company&amp;#x2019;s and Roche&amp;#x2019;s receipt of notice, subject to
prior resolution of the matter before the court. Additionally,
ACTONEL OaM had FDA exclusivity through April 2011, and Mylan did
not certify against the underlying &amp;#x2018;122 Patent which expires
in June 2014 (including a 6-month pediatric extension of regulatory
exclusivity) and covers all of the Company&amp;#x2019;s ACTONEL
products. As a result, the Company does not believe that Mylan will
be permitted to market its proposed ANDA products prior to the
expiration of Teva&amp;#x2019;s 180-day period of marketing exclusivity
following the June 2014 expiration of the &amp;#x2018;122 Patent
(including a 6-month pediatric extension of regulatory
exclusivity). In addition, the &amp;#x2018;938 Patent covering ACTONEL
OaM expires in 2023.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In October,
November and December 2010 and February 2011, the Company and Roche
received Paragraph IV certification notice letters from Sun,
Apotex, Teva and Mylan, respectively, indicating that each such
company had amended its existing ANDA covering generic versions of
ACTONEL OaM to include Roche&amp;#x2019;s new U.S. Patent
No.&amp;#xA0;7,718,634 (the &amp;#x201C;&amp;#x2018;634 Patent&amp;#x201D;). The
notice letters contended that the &amp;#x2018;634 Patent, a method
patent expiring in November 2023 (including a 6-month pediatric
extension of regulatory exclusivity) which Roche licensed to PGP
with respect to ACTONEL OaM, was invalid, unenforceable or not
infringed. The Company and Roche filed patent infringement suits
against Sun and Apotex in December 2010, against Teva in January
2011 and against Mylan in March 2011 in the U.S. District Court for
the District of Delaware charging each with infringement of the
&amp;#x2018;634 Patent. We believe that no additional 30-month stay is
available in these matters because the &amp;#x2018;634 Patent was listed
in the FDA&amp;#x2019;s Orange Book subsequent to the date on which Sun,
Apotex, Teva and Mylan filed their respective ANDAs with respect to
ACTONEL OaM. ACTONEL OaM had FDA exclusivity through April 2011,
and the underlying &amp;#x2018;122 Patent, which covers all of the
Company&amp;#x2019;s ACTONEL products, expires in June 2014 (including a
6-month pediatric extension of regulatory exclusivity).&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company and
Roche&amp;#x2019;s actions against Teva, Apotex, Sun and Mylan for
infringement of the &amp;#x2018;938 Patent and the &amp;#x2018;634 Patent
arising from each such party&amp;#x2019;s proposed generic version of
ACTONEL OaM have been consolidated for pretrial purposes. Trial for
the suits relating to the &amp;#x2018;938 Patent has been scheduled for
July 2012. No trial date has been set for the suits relating to the
&amp;#x2018;634 Patent. While the Company and Roche intend to vigorously
defend the &amp;#x2018;938 Patent and the &amp;#x2018;634 Patent and protect
their legal rights, the Company can offer no assurance as to when
the lawsuits will be decided, whether the lawsuits will be
successful or that a generic equivalent of ACTONEL OaM will not be
approved and enter the market prior to the expiration of the
&amp;#x2018;938 Patent and the &amp;#x2018;634 Patent in 2023.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;DORYX Patent
Matters&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;As a result of
the enactment of the QI Program Supplemental Funding Act of 2008
(the &amp;#x201C;QI Act&amp;#x201D;) on October&amp;#xA0;8, 2008, Mayne Pharma
International Pty. Ltd.&amp;#x2019;s (&amp;#x201C;Mayne&amp;#x201D;) U.S. Patent
No.&amp;#xA0;6,958,161 (the &amp;#x201C;&amp;#x2018;161 Patent&amp;#x201D;) covering
the Company&amp;#x2019;s DORYX product was submitted to the FDA for
listing in the FDA&amp;#x2019;s Orange Book and potential generic
competitors that had filed an ANDA prior to the listing of the
&amp;#x2018;161 Patent were permitted to certify to the listed patent
within 120 days of the enactment of the QI Act. In November and
December 2008, and January 2009, the Company and Mayne received
Paragraph IV certification notice letters from Actavis Elizabeth
LLC (&amp;#x201C;Actavis&amp;#x201D;), Mutual Pharmaceutical Company, Inc.
(&amp;#x201C;Mutual&amp;#x201D;), Mylan, Impax Laboratories, Inc.
(&amp;#x201C;Impax&amp;#x201D;) and Sandoz Inc. (&amp;#x201C;Sandoz&amp;#x201D;)
indicating that each had submitted to the FDA an ANDA seeking
approval to manufacture and sell generic versions of DORYX 100 and
75 mg delayed-release tablets (&amp;#x201C;DORYX 100 and 75&amp;#x201D;).
Those notice letters contend that the &amp;#x2018;161 Patent is invalid,
unenforceable or not infringed. In December 2008 and January 2009,
the Company and Mayne filed lawsuits against each of the potential
generic competitors in the United States District Court for the
District of New Jersey, charging them with infringement of the
&amp;#x2018;161 Patent. In March 2009, the Company received the
FDA&amp;#x2019;s response to a citizen petition that it had submitted
requesting that the FDA impose a 30-month stay of approval on ANDAs
referencing DORYX 100 and 75 that were filed prior to the listing
of the &amp;#x2018;161 Patent under the transition rules of the QI Act.
In its joint response to the citizen petitions of the Company and
several other petitioners, the FDA took the position that a
30-month stay would not apply to approvals for such ANDAs. On
November&amp;#xA0;9, 2009, pursuant to an agreement among the Company,
Mayne and Mutual, the District Court dismissed the lawsuit against
Mutual concerning generic versions of DORYX 100 and 75 following
Mutual&amp;#x2019;s agreement to withdraw its ANDA with respect to such
products. In March 2011, the Company entered into a settlement
agreement with Actavis pursuant to which Actavis agreed, among
other things, not to market or sell a generic equivalent of Doryx
100 and 75 until December&amp;#xA0;15, 2016, subject to certain
exceptions and conditions. In April 2011, the Company&amp;#x2019;s
action against Actavis was dismissed without prejudice.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In March 2009,
the Company and Mayne received Paragraph IV certification notice
letters from Impax and Mylan indicating that each had submitted to
the FDA an ANDA seeking approval to manufacture and sell a generic
version of DORYX 150 mg delayed-release tablets (&amp;#x201C;DORYX
150&amp;#x201D;). The notice letters contend that the &amp;#x2018;161 Patent
is not infringed. In March 2009, the Company and Mayne filed a
lawsuit against Impax in the United States District Court for the
District of New Jersey, charging Impax with infringement of the
&amp;#x2018;161 Patent. In May 2009, the Company and Mayne filed a
lawsuit against Mylan in the United States District Court for the
District of New Jersey charging Mylan with infringement of the
&amp;#x2018;161 Patent. Based on the FDA&amp;#x2019;s March 2009 response,
the Company believes that because each of Impax&amp;#x2019;s and
Mylan&amp;#x2019;s ANDAs with respect to generic versions of DORYX 150
were submitted after the listing of the &amp;#x2018;161 Patent in the
FDA&amp;#x2019;s Orange Book, that the FDA will stay approval of these
generic versions of the product for up to 30 months, subject to the
prior resolution of the matter before the District
Court.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In January 2010,
the Company and Mayne received a Paragraph IV certification notice
letter from Sandoz indicating that it had amended its ANDA
previously submitted to the FDA requesting approval to manufacture
and sell generic versions of DORYX 100 and 75 to include a generic
version of DORYX 150. The notice letter contends that the
&amp;#x2018;161 Patent is invalid, unenforceable or not infringed. In
January 2010, the Company and Mayne filed a lawsuit against Sandoz
in the United States District Court for the District of New Jersey
charging Sandoz with infringement of the &amp;#x2018;161 Patent with
respect to DORYX 150. While the Company can give no assurance, it
believes that under current law, the FDA may not approve
Sandoz&amp;#x2019;s amended ANDA with respect to DORYX 150 until 180
days following the date on which the &amp;#x201C;first filer&amp;#x201D; of
an ANDA with respect to DORYX 150 enters the market, unless the
first filer transfers or forfeits its first filer rights, for
example by failing to timely receive tentative approval of its
product or begin marketing its product in a timely
manner.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In February
2010, the Company and Mayne received a Paragraph IV certification
notice letter from Heritage Pharmaceuticals Inc.
(&amp;#x201C;Heritage&amp;#x201D;) indicating that it had submitted to the
FDA an ANDA seeking approval to manufacture and sell a generic
version of DORYX 100 and 75 and DORYX 150. In March 2010, the
Company and Mayne filed a lawsuit against Heritage in the United
States District Court for the District of New Jersey charging
Heritage with infringement of the &amp;#x2018;161 Patent. In December
2010, the Company entered into a settlement agreement with Heritage
pursuant to which Heritage agreed, among other things, not to
market or sell generic equivalents of DORYX 100 and 75 and DORYX
150 until December&amp;#xA0;15, 2016, subject to certain exceptions and
conditions. In February 2011, the Company&amp;#x2019;s action against
Heritage was dismissed without prejudice.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;All of the
actions against Mylan, Impax and Sandoz have been consolidated for
discovery purposes. No trial dates have been set by the District
Court. In December 2010, the FDA approved Impax&amp;#x2019;s and
Mylan&amp;#x2019;s ANDAs with respect to generic versions of DORYX 100
and 75, and the Company believes that generic versions of these
products were launched &amp;#x201C;at-risk&amp;#x201D; in January 2011. DORYX
100 and 75 represent less than 5% of our DORYX franchise based on
total prescriptions according to IMS Health, Inc., while DORYX 150
currently represents the remainder of the DORYX franchise. If the
FDA approves Impax&amp;#x2019;s or Mylan&amp;#x2019;s ANDAs with respect to
DORYX 150 following the expiration of the applicable 30-month stay
in September 2011, and Impax or Mylan elects to launch
&amp;#x201C;at-risk&amp;#x201D;, a generic equivalent of DORYX 150 could also
enter the market prior to the expiration of the &amp;#x2018;161 Patent
in 2022. While the Company and Mayne intend to vigorously defend
the &amp;#x2018;161 Patent and pursue all of their legal rights,
including their right to any monetary damages, the Company can
offer no assurance as to when the lawsuits will be decided, whether
the lawsuits will be successful or that additional generic
equivalents of DORYX 100 or 75, or any generic equivalent of DORYX
150, will not be approved and enter the market prior to the
expiration of the &amp;#x2018;161 Patent in 2022.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;LOESTRIN 24 FE Patent
Matters&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In April 2011,
the Company received a Paragraph IV certification notice letter
from Mylan, as U.S. agent for Famy Care Ltd. (&amp;#x201C;Famy
Care&amp;#x201D;), indicating that Famy Care had submitted to the FDA an
ANDA seeking approval to manufacture and sell a generic version of
the Company&amp;#x2019;s oral contraceptive, LOESTRIN 24 FE. The notice
letter contends that the Company&amp;#x2019;s U.S. Patent
No.&amp;#xA0;5,552,394 (the &amp;#x201C;&amp;#x2018;394 Patent&amp;#x201D;), which
covers LOESTRIN 24 FE and expires in 2014, is invalid,
unenforceable or not infringed. The Company is reviewing the Famy
Care notice letter and expects to file an infringement lawsuit
against Famy Care and Mylan within 45 days of its receipt of the
Paragraph IV certification notice letter. If the Company files suit
against Famy Care within 45 days, the FDA will be prohibited from
approving Famy Care&amp;#x2019;s ANDA for 30 months from the date of the
Company&amp;#x2019;s receipt of the Famy Care notice letter, subject to
the prior resolution of the matter before the court. In January
2009, the Company entered into a settlement and license agreement
with Watson to resolve patent litigation related to the &amp;#x2018;394
Patent. Under the agreement, Watson agreed, among other things, not
to commence marketing its generic equivalent product until the
earliest of (i)&amp;#xA0;January&amp;#xA0;22, 2014, (ii)&amp;#xA0;180 days
prior to a date on which the Company has granted rights to a third
party to market a generic version of LOESTRIN 24 FE in the U.S. or
(iii)&amp;#xA0;the date on which a third party enters the market with a
generic version of LOESTRIN 24 FE in the U.S. without authorization
from the Company. In addition, under current law, unless Watson
forfeits its &amp;#x201C;first filer&amp;#x201D; status, the FDA may not
approve later-filed ANDAs until 180 days following the date on
which Watson enters the market. However, the Company believes
Watson may have forfeited its &amp;#x201C;first filer&amp;#x201D; status as a
result of its failure to obtain approval by the FDA of its ANDA
within the requisite period. In October 2010, the Company also
entered into a settlement and license agreement with Lupin Ltd. and
its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (collectively
&amp;#x201C;Lupin&amp;#x201D;), to resolve patent litigation related to the
&amp;#x2018;394 Patent. Under that agreement, Lupin and its affiliates
agreed, among other things, not to market or sell a generic
equivalent product until the earlier of July&amp;#xA0;22, 2014 or the
date of an &amp;#x201C;at-risk&amp;#x201D; entry into the U.S. market by a
third party generic version of LOESTRIN 24 FE. While the Company
intends to vigorously defend the &amp;#x2018;394 Patent and pursue its
legal rights, it can offer no assurance that a generic equivalent
of LOESTRIN 24 FE will not be approved and enter the market prior
to the expiration of the &amp;#x2018;394 Patent in 2014.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;False Claims Act
Litigation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In December
2009, the Company was served with a civil complaint brought by an
individual plaintiff, purportedly on behalf of the United States,
alleging that the Company and over 20 other pharmaceutical
manufacturers violated the False Claims Act (&amp;#x201C;FCA&amp;#x201D;), 31
U.S.C. &amp;#xA7; 3729(a)(1)(A), (B), by submitting false records or
statements to the federal government, thereby causing Medicaid to
pay for unapproved or ineffective drugs. The plaintiff&amp;#x2019;s
original complaint was filed under seal in 2002, but was not served
on the Company until 2009. The complaint alleges that the Company
submitted to the Centers for Medicare and Medicaid Services
(&amp;#x201C;CMS&amp;#x201D;) false information regarding the safety and
effectiveness of certain nitroglycerin transdermal products. The
plaintiff alleges that CMS included these products in its list of
reimbursable prescription drugs and that, as a consequence federal
Medicaid allegedly reimbursed state Medicaid programs for a portion
of the cost of such products. The plaintiff asserts that from 1996
until 2003 the federal Medicaid program paid approximately $9.8
million to reimburse the states for the Company&amp;#x2019;s
nitroglycerin transdermal products. The complaint seeks, among
other things, treble damages; a civil penalty of up to ten thousand
dollars for each alleged false claim; and costs, expenses and
attorneys&amp;#x2019; fees.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company has
requested all prior versions of plaintiff&amp;#x2019;s complaint and
expects to file its response to the complaint following its receipt
and review of the prior versions. The Company intends to defend
this action vigorously and currently believes that the complaint
lacks merit. The Company has a number of defenses to the
allegations in the complaint and anticipates filing a motion to
dismiss the action. In addition, the United States has declined to
intervene in this action with respect to the Company. Although it
is impossible to predict with certainty the outcome of any
litigation, an unfavorable outcome in these proceedings is not
anticipated. An estimate of the range of potential loss to the
Company, if any, relating to these proceedings is not possible at
this time.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Fair Labor Standards
Act and Related Litigation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In August 2010,
the Company was served with a complaint in a class and collective
action brought under the Fair Labor Standards Act and the
Illinois&amp;#x2019; Minimum Wage Law. The lawsuit was filed in the
United States District Court for the Northern District of Illinois
by a former pharmaceutical sales representative of the Company, on
behalf of herself and other sales representatives. The suit alleges
that the Company improperly categorized its pharmaceutical sales
representatives as &amp;#x201C;exempt&amp;#x201D; rather than
&amp;#x201C;non-exempt&amp;#x201D; employees and as a result, wrongfully
denied them overtime compensation. Plaintiff is seeking damages for
unpaid overtime, including backpay, liquidated damages, penalties,
interest, and attorneys&amp;#x2019; fees. Other pharmaceutical companies
have been the subject of similar lawsuits. The Company believes it
has meritorious defenses and intends to defend this action
vigorously. This case is in the early stages of litigation, and an
estimate of the range of potential losses to the Company, if any,
relating to these proceedings is not possible at this
time.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</wcrx:LegalProceedingsTextBlock>
  <wcrx:AcquisitionsTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;4.
Acquisitions&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Enablex&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company and
Novartis Pharmaceuticals Corporation (&amp;#x201C;Novartis&amp;#x201D;) were
parties to an agreement to co-promote ENABLEX, developed by
Novartis, in the U.S. The Company shared development and
promotional expenses with Novartis pursuant to the agreement and
those costs were included within selling, general and
administrative (&amp;#x201C;SG&amp;amp;A&amp;#x201D;) expenses. The Company
received a contractual percentage of Novartis&amp;#x2019; sales of
ENABLEX, which was recorded, on a net basis, in other revenue. For
the quarter ended March&amp;#xA0;31, 2010, the Company recognized other
revenue related to ENABLEX of $18,180.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
October&amp;#xA0;18, 2010, the Company acquired the U.S. rights to
ENABLEX from Novartis for an upfront payment of $400,000 in cash at
closing, plus future milestone payments of up to $20,000 in the
aggregate based on 2011 and 2012 net sales of ENABLEX (the
&amp;#x201C;ENABLEX Acquisition&amp;#x201D;). Concurrent with the closing of
the ENABLEX Acquisition, the Company and Novartis terminated their
existing co-promotion agreement, and the Company assumed full
control of sales and marketing of ENABLEX in the U.S.
market.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;PGP&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
October&amp;#xA0;30, 2009, the Company acquired the global branded
prescription pharmaceutical business (&amp;#x201C;PGP&amp;#x201D;) of The
Proctor&amp;#xA0;&amp;amp; Gamble Company (&amp;#x201C;P&amp;amp;G&amp;#x201D;) for
$2,919,261 in cash and the assumption of certain liabilities (the
&amp;#x201C;PGP Acquisition&amp;#x201D;). Under the terms of the purchase
agreement pursuant to which the Company acquired PGP, the Company
acquired P&amp;amp;G&amp;#x2019;s portfolio of branded pharmaceutical
products, prescription drug pipeline, manufacturing facilities in
Puerto Rico and Germany and a net receivable owed from P&amp;amp;G of
approximately $60,000. The total purchase price of $2,919,261 was
allocated to the fair value of the assets acquired and liabilities
assumed as of the acquisition date. In the quarter ended
March&amp;#xA0;31, 2010, the Company recorded an expense, as a
component of its cost of sales, of $105,504 as a result of the
purchase accounting fair value step-up on inventories acquired in
the PGP Acquisition as such inventories were sold to its customers.
No such expense was recorded in the quarter ended March&amp;#xA0;31,
2011.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</wcrx:AcquisitionsTextBlock>
  <wcrx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;10. Accrued Expenses and
Other Current Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Accrued expenses
and other current liabilities consisted of the
following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="84%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="70%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;As of&lt;br /&gt;
March&amp;#xA0;31,&amp;#xA0;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;As of&lt;br /&gt;
December&amp;#xA0;31,&amp;#xA0;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Product rebate accruals
(commercial and government)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;270,723&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;254,662&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Sales return
reserves&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;131,965&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;129,621&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Severance
accruals&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;55,329&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5,975&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Payroll, commissions, and
employee costs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;36,380&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;35,513&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Customer loyalty and coupon
programs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;36,145&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;70,758&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;ACTONEL co-promotion
liability&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;35,370&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;84,652&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Professional fees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;20,073&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;20,081&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Contractual
obligations&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;15,880&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;15,880&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Withholding taxes&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11,447&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11,621&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Research and development
expense accruals&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;10,075&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11,313&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Uncertain tax
positions&lt;/font&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;sup style="vertical-align:baseline; position:relative; bottom:.8ex"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;9,526&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;9,526&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Interest payable&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;8,899&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;35,826&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Obligations under product
licensing and distribution agreements&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;7,987&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;9,094&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Value-added tax
liabilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,786&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;6,434&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Advertising and
promotion&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;4,305&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5,876&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Deferred income&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,954&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,460&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;26,403&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;21,538&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;688,247&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;730,830&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="3%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;(1)&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;As of March&amp;#xA0;31, 2011
and December&amp;#xA0;31, 2010, all income tax liabilities were related
to reserves recorded under ASC Topic 740 &amp;#x201C;Accounting for
Income Taxes,&amp;#x201D; (&amp;#x201C;ASC 740&amp;#x201D;). In addition, reserves
included as a component of other non-current liabilities as of
March&amp;#xA0;31, 2011 and December&amp;#xA0;31, 2010 totaled
$77,289.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</wcrx:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
  <wcrx:InterestExpenseNet contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">155025000</wcrx:InterestExpenseNet>
  <wcrx:RetirementAndDefinedCompensationPlansDisclosuresTextBlock contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0">&lt;div&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;19. Retirement
Plans&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company has
defined benefit retirement pension plans covering certain employees
in Western Europe. Retirement benefits are generally based on an
employee&amp;#x2019;s years of service and compensation. Funding
requirements are determined on an individual country and plan basis
and are subject to local country practices and market
circumstances. The Swiss plan is partially employee funded, but the
employee contributions were not material.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The net periodic
benefit cost of the Company&amp;#x2019;s non-U.S. defined benefit plans
for the quarters presented were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" align="center"&gt;
&lt;tr&gt;
&lt;td width="80%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;Quarter&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;b&gt;2010&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Service cost&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;567&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;529&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Interest cost&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,091&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,049&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected return on plan
assets&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(1,064&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(864&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Amortization of:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Actuarial losses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(45&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Prior service
costs&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(33&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;)&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:1px solid #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Net periodic benefit
cost&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;516&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;714&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom" style="border-top:3px double #000000"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Company
Contributions&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:4%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;For the quarter
ended March&amp;#xA0;31, 2011, the Company contributed $1,291 to
non-U.S. retirement plans.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</wcrx:RetirementAndDefinedCompensationPlansDisclosuresTextBlock>
  <wcrx:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-53989000</wcrx:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
  <wcrx:IncreaseDecreaseAccountsReceivablePrepaidAndOtherAssets contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">-52713000</wcrx:IncreaseDecreaseAccountsReceivablePrepaidAndOtherAssets>
  <wcrx:RepaymentsOfPriorBankDebt contextRef="eol_PE670978--1110-Q0003_STD_90_20110331_0" unitRef="iso4217_USD" decimals="-3">3418980000</wcrx:RepaymentsOfPriorBankDebt>
  <context id="eol_PE670978--1110-Q0003_STD_90_20110331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE670978--1110-Q0003_STD_90_20100331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE670978--1110-Q0003_STD_365_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE670978--1110-Q0003_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE670978--1110-Q0003_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE670978--1110-Q0003_STD_0_20110429_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <instant>2011-04-29</instant>
    </period>
  </context>
  <context id="eol_PE670978--1110-Q0003_STD_0_20110331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <instant>2011-03-31</instant>
    </period>
  </context>
  <context id="eol_PE670978--1110-Q0003_STD_0_20100331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001323854</identifier>
    </entity>
    <period>
      <instant>2010-03-31</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
</xbrl>